Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company
Case Number:
17-1694
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
February 07, 2019
Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar
Momenta Pharmaceuticals Inc. can't challenge a patent for Bristol-Myers Squibb Co.'s rheumatoid arthritis drug Orencia because Momenta has stopped developing a biosimilar version of the blockbuster product, the Federal Circuit ruled Thursday.
-
November 06, 2018
Orencia Patent Appeal Not Moot, Momenta Tells Fed. Circ.
An infringement case over a Bristol-Myers Squibb Co. patent covering its Orencia biologics product is not moot simply because challenger Momenta Pharmaceuticals Inc. is considering stopping development of a proposed biosimilar, Momenta has told the Federal Circuit.
-
December 05, 2017
Pharma Co. Slams Patent Challenge Standing In Fed. Circ.
Pharmaceuticals company Bristol-Myers Squibb Co. asked the Federal Circuit Tuesday to reject for lack of standing a competitor's appeal of a U.S. Patent Trial and Appeal Board decision upholding its patent for a biologics product, saying the company cannot show injury because it has not yet developed a product that infringes the patent.